Perimenopausal females Other
Conditions
Interventions
This study has two nutrition supplement groups, which are consumed twice daily for 12 weeks. They consist of:
1. Intervention: 350 g high protein 0% Greek Yogurt
2. Energy and protein matched control
Sponsors
Dairy Farmers Of Canada
Eligibility
Sex/Gender
Female
Age
35 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Be in the perimenopausal period (Stage -1 or -2 assessed using the STRAW+10 guidelines) . 2. Be untrained/sedentary (<2 structured exercise sessions per week). 3. Low habitual dairy consumption (=1 serving of milk, yogurt, cheese/day). 4. Be able to maintain a habitual diet and safe to perform RET three times per week throughout the trial (assessed by the “Get Active” Questionnaire). 5. Understand the study procedures and provide informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Regular use of tobacco- or cannabis-related products (smoking, chewing or vaping). 2. Have any electronic medical or metal implants. 3. Currently pregnant or planning to get pregnant. 4. Allergy to dairy foods or lactose intolerance. 5. Orthopaedic conditions (MSK injury, chronic back pain etc) that may worsen with exercise. 6. Any acute or chronic illness relating to the cardiac, pulmonary, skeletal or neuromuscular systems, Type 1 diabetes or unmanaged hypertension, lipidaemia or cardiovascular disease or any other medical concern that may interfere with their ability to safely complete the study. 7. Regular use of medications known to affect protein metabolism or inflammation (i.e. corticosteroids, non-steroidal anti-inflammatory drugs (prescription use or daily use of over-the-counter medication), or prescription strength acne medications). 8. Concurrent participation in a research study that may interfere with the results of the current study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body composition measured using dual x-ray absorptiometry (DXA) at baseline and after 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Skeletal muscle mass measured using D3-creatine at baseline and after 12 weeks 2. Skeletal muscle characteristics measured using muscle biopsy at baseline and after 12 weeks 3. Gut microbiome diversity from fecal samples measured using 16S gene sequencing at baseline and after 12 weeks 4. Menopausal symptoms, sleep, mood and GI disturbances measured by questionnaires (Menopause Specific Quality of Life Questionnaire, Pittsburgh Sleep Quality Index, Profile of Mood State, PROMIS-GI) at baseline and after 12 weeks 5. Muscle strength assessments measured using 5-Repetition Maximum (5RM) at baseline and after 12 weeks | — |
Countries
Canada
Contacts
Public ContactJoel Prowting
Outcome results
None listed